Effect of atorvastatin and rosuvastatin on glucose intolerance in low dose streptozotocin induced hyperglycemic Albino rats


  • Manju Gari Department of Pharmacology, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India
  • Abhishek Kumar Department of Pharmacology, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India
  • Lakhan Majhee Department of Pharmacology, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India




Atorvastatin, Glucose tolerance, Hydrophilic, Rosuvastatin, Streptozotocin


Background: Dyslipidemia and glucose intolerance are closely associated with each other especially as a part of metabolic syndrome. Statins are the drug of choice for treatment of dyslipidemia and for primary prevention of coronary heart disease in diabetics. Recent studies indicate risk of new onset diabetes in patients receiving statins. Hence it was worthwhile to study the effect of two most commonly used statins, which differ in their lipophilicity, on glucose tolerance in prediabetic animal model.

Methods: The study consisted of 3 groups with 6 wistar rats in each and hyperglycemia was induced by intraperitoneal injection of low dose (25mg/kg) streptozotocin. Group 1 served as control, group 2 and 3 were given Atorvastatin and Rosuvastatin respectively for 8 weeks. Oral glucose tolerance test (OGTT) was performed at 0,1 and 2 hrs after glucose load on days 0, 14, 28, 42 and 56 days.

Results: Starting from 28th day onwards both the treatment groups showed progressive worsening of glucose tolerance throughout the study period in comparison to the control. The impairing effect on glucose tolerance was less pronounced in Rosuvastatin group as compared to Atorvastatin.

Conclusions: Hydrophilic Rosuvastatin showing less impairing effect on glucose tolerance can be a rational choice than lipophilic Atorvastatin for prevention and control of dyslipidemia in patients at risk of developing frank diabetes or having impaired glucose tolerance.


Blood pressure, cholesterol, and stroke in eastern Asia: Eastern stroke and coronary heart disease collaborative research group. Lancet 1998;352:1801-7.

Fuentes R, Uusitalo T, Puska P, Tuomilehto J, Nissinen A. Blood cholesterol level and prevalence of hypercholesterolaemia in developing countries: a review of population-based studies carried out from 1979 to 2002. Eur J Cardiovasc Prev Rehabil. 2003;10:411-9.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. The Lancet. 2002 Jul 6;360(9326):7-22.

Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. Goodman and Gilman’s, The Pharmacological Basis of Therapeutics. McGraw-Hill. 2011:877-908.

Oda E. Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol. 2012 Apr;49(2):89-95.

Batsis JA, Nieto-Martinez RE, Lopez-Jimenez F. Metabolic syndrome: from global epidemiology to individualized medicine. Clin Pharmacol Ther. 2007 Nov;82(5):509-24.

Levitan EB, Song Y, Ford ES, Liu S. Is non-diabetic hyperglycemia a risk factor for cardiovascular disease? A metaanalysis of prospective studies. Arch Intern Med. 2004;164:2147-55.

Saad MF, Kowler WC, Pettitt DJ, Nelson RG, Bennett PH. Transient impaired glucose tolerance in Pima Indians: Is it important? Br Med J. 1988;297:1438-41.

Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacyand safety of statin treatment for cardiovascular disease: a network meta-analysis of 170, 255 patients from 76 randomized trials. QJM. 2011;104:109-24.

Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32:1924-9.

Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet. 2010 Mar 5;375(9716):735-42.

Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. Jama. 2011 Jun 22;305(24):2556-64.

Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of newonset type 2 diabetes: a metaanalysis of randomized controlled trials. Curr Med Res Opin. 2008;24:1359-62.

Tandon V, Bano G, Khajuria V, Parihar A, Gupta S. Pleiotropic effects of statins. Indian J Pharmacol. 2005;37:77-85.

Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. The American journal of cardiology. 2005 Sep 5;96(5):11-23.

Bonsu KO, Kadirvelu A, Reidpath DD. Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis. Systematic reviews. 2013 Apr 23;2(1):22.

Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117-25.

Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. The Lancet. 2006 Sep 15;368(9539):919-28.

Medhi B, Prakash A. Practical manual of experimental and clinical pharmacology. Jaypee Brothers Medical Publishers; 2010:24.

Satoh K, Keimatsu N, Kanda M, Kasai T, Takaguri A, Sun F, et al. HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats. Biological and Pharmaceutical Bulletin. 2005;28(11):2092-5.

Makoto K, Satoh K, Ichihara K. Effects of Atorvastatin and Pravastatin on Glucose Tolerance in Diabetic Rats Mildly Induced by StreptozotocinBiol. Pharm. Bull. 2003;26(12):1681-4.

Ganda OP, Rossini AA, Like AA. Studies on streptozotocin diabetes. Diabetes. 1976 Jul 1;25(7):595-603.

Ding PY, Hsu P, Lu T. Statin Therapy on Insulin Resistance and Plasma Level of Adiponectin in Non Diabetic, Hypercholesterolemic Patients. Acta Cardiol Sin. 2009;25:183-9.

Amarenco P. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-59.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.

Metz SA, Rabaglia ME, Stock JB, Kowluru A. Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. Biochem J. 1993;295(Pt 1):31-40.

Ohrvall M, Lithell H, Johansson J, Vessby B. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism. 1995;44:212-7.

Sampson UK, Linton MF, Fazio S. Are statins diabetogenic?. Current opinion in cardiology. Jul 2011;26(4):342-7.




How to Cite

Gari, M., Kumar, A., & Majhee, L. (2017). Effect of atorvastatin and rosuvastatin on glucose intolerance in low dose streptozotocin induced hyperglycemic Albino rats. International Journal of Basic & Clinical Pharmacology, 6(7), 1747–1752. https://doi.org/10.18203/2319-2003.ijbcp20172742



Original Research Articles